Diabetes and liver medications failed to treat long COVID
Medical Xpress
March 3, 2026
AI-Generated Deep Dive Summary
A recent clinical trial has revealed that metformin and ursodeoxycholic acid (UDCA), commonly used medications for diabetes and liver conditions, respectively, do not effectively alleviate symptoms of long COVID. Despite prior evidence suggesting metformin might reduce long-term risks when taken during acute infection, a two-week course of either drug failed to meaningfully improve recovery in patients with persistent symptoms. The study, published in the *Annals of Internal Medicine*, highlights the ongoing challenge of finding effective treatments for long COVID.
Long COVID, characterized by lingering symptoms such as fatigue, respiratory issues, and cognitive dysfunction, affects millions worldwide. Researchers had hoped these medications might offer a solution due to their anti-inflammatory properties and safety profiles. However, the trial involving 1,000 participants found no significant differences in symptom improvement between those who took metformin or UDCA and those who received placebos.
The randomized, double-blind study was one of the largest of its kind focused on long COVID treatments. While both drugs showed minor improvements in specific symptoms like fatigue and嗅觉 changes (olfactory disturbances), these effects were not clinically significant. This underscores the need for further research into alternative therapies, as current options remain limited and ineffective.
The findings emphasize the urgent need for more effective treatments to address the growing burden of long COVID. While this study concludes that metformin and UDCA are not viable solutions, it also highlights the importance of continued innovation in identifying better treatment options. Patients and healthcare providers remain hopeful as researchers explore other potential therapies and approaches to managing this complex condition.
This lack of proven treatments underscores the critical need for ongoing research into long COVID's underlying mechanisms and effective interventions. As the scientific community continues to investigate, the focus remains on finding safe and reliable solutions to improve quality of life for those affected by this mysterious post-viral syndrome.
Verticals
healthmedical
Originally published on Medical Xpress on 3/3/2026